25.09.2012 • NewsBPoil industryoil industry Russia

TNK-BP Signs $675 Million Loan

Russia's third-largest oil company TNK-BP signed a $675 million loan with a group of banks, falling short of its targeted $750 million after one bank was unable to commit to the financing, banking sources said on Tuesday.

Nine banks - Bank of America, Barclays, Citibank, ING, Mizuho, Raiffeisen Bank, Royal Bank of Scotland, Societe Generale and Unicredit - provided $75 million each for the financing, which the company will use for general corporate purposes.

A tenth bank was unable to provide its $75 million commitment to the loan after it failed to get approval from its credit committee, one banker said.

The banker said that the tenth bank may have been conflicted in providing the financing as Russian state-controlled peer Rosneft is in talks with 12 to 14 banks to raise around $15 billion in financing to potentially buy BP's 50% stake in TNK-BP.

TNK-BP is facing a hike in pricing on its new three-year loan, which pays a margin of 270 basis points (bps) over Libor compared with 130 bps for the borrower's previous $1.5 billion four-year deal signed in August 2011.

TNK-BP declined to comment.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.